Triptorelin acetate
PreclinicalSmall molecule
IpsenTriptorelin acetate is one of 54 small molecule programs targeting CLE. It is currently in Preclinical.
2
Indications
14
Total Trials
0
Active Trials
53
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
57 competitors in Endometriosis
#DrugCompanyPhaseTrials
1Danocrine
SanofiApproved
Bayer Aspirin
BayerApproved
IC-Green
PProvepharm SAS
Approved
Estrace
Novo NordiskApproved
Ketalar
AAultman Health Foundation
Approved
Trelstar
OOncoVerity, Inc.
Approved
Flagyl
DDePuy Orthopaedics
Approved
Implanon
OOrganon and Co
Approved
Zocor
OOrganon and Co
Approved
Catapres
Boehringer IngelheimApproved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
GnRH Antagonist3 trials
Effect of GnRH Agonist vs GnRH Antagonist on IVF/ICSI Outcomes.
Completed·—·Phase 4·NCT04724343·50 enrolled
Effect of GnRH Agonist vs GnRH Antagonist on Oocyte Morphology During IVF/ICSI
Completed·—·Phase 4·NCT04724486·50 enrolled
Endometriosis2 trials
Polycystic Ovary Syndrome2 trials
Effect of GnRH Agonist vs GnRH Antagonist on IVF/ICSI Outcomes in Polycystic Ovary Syndrome Patients.
Completed·—·Phase 4·NCT04727671·50 enrolled
Effect of GnRH Agonist vs GnRH Antagonist on Oocyte Morphology in Polycystic Ovary Syndrome Patients During IVF/ICSI
Completed·—·Phase 4·NCT04727684·50 enrolled
Ovarian Hyperstimulation1 trial
Adenomyosis1 trial
Long-term Use of Mifepristone in the Treatment of Adenomyosis
Unknown status·WWomen's Hospital School Of Medicine Zhejiang University·Phase 1·NCT05151016·140 enrolled
5 more indications
Embryo Transfer1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Triptorelin acetate. EMBL-EBI & Wellcome Sanger Institute.
- [4]